Log In
Print this Print this

DCVax-Brain (DCVax-L)

  Manage Alerts
Collapse Summary General Information
Company Northwest Biotherapeutics Inc.
DescriptionAutologous dendritic cells treated ex vivo with glioblastoma tumor fragments
Molecular Target Not applicable
Mechanism of ActionImmune modulation
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase III
Standard IndicationBrain cancer
Indication DetailsTreat glioblastoma multiforme (GBM); Treat malignant gliomas; Treat newly diagnosed glioblastoma multiforme (GBM)
Regulatory Designation EU - Promising Innovative Medicine (Treat glioblastoma multiforme (GBM));
EU - Promising Innovative Medicine (Treat malignant gliomas);
EU - Promising Innovative Medicine (Treat newly diagnosed glioblastoma multiforme (GBM))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today